6533b820fe1ef96bd127a288

RESEARCH PRODUCT

German Adjuvant Intergroup Node Positive (GAIN) study: A phase III trial to compare IDD-ETC versus EC-TX in patients with node-positive primary breast cancer—Final efficacy analysis.

Ingo BauerfeindB. ConradValentina NekljudovaHans TeschAndreas SchneeweissMarcus SchmidtGunter Von MinckwitzD. EllingChristian JackischTanja FehmNadia HarbeckChristoph ThomssenMichael UntchJens HuoberVolkmar MüllerVolker MoebusHans-joachim LueckSibylle Loibl

subject

GynecologyOncologyCancer Researchmedicine.medical_specialtyCyclophosphamidebusiness.industrymedicine.medical_treatmentchemistry.chemical_compoundOncologyPaclitaxelchemistryInternal medicinemedicineOverall survivalIn patientskin and connective tissue diseasesbusinessPrimary breast cancerAdjuvantmedicine.drugEpirubicin

description

1009 Background: Intense dose-dense (idd) epirubicin (E), paclitaxel (T), cyclophosphamide (C) (idd-ETC) resulted in a superior disease-free (DFS) and overall survival (OS) compared to conventional...

https://doi.org/10.1200/jco.2014.32.15_suppl.1009